|
Subject: An multicentric, observational retrospective, cross-sectional survey study to assess the prescription pattern of Acebrophylline in Asthma
Asthma is a very common disease in worldwide population, in which almost 1 in 10 children and 1 in 12 adults are affected. According to Global Asthma Report 2018, 339 million people are affected worldwide.1 Asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity (BHR) which leads to overproduction of mucus, airway narrowing and airway wall remodelling by reacting to non-specific stimuli (such as exercise and cold air) on smooth muscle cells in people with asthma.2
According to GINA (Global Initiative for Asthma), the goal of treatment in ASTHMA is to: achieve total control and to reduce inflammation.3 Clinicians commonly use various pharmacological treatments in the management of asthma to relieve symptoms, improve quality of life, enhance exercise tolerance, prevent and treat exacerbations. The main strategy to be considered in the pharmacological treatment of asthma are bronchodilators; short-acting bronchodilators (β -agonist and anti- cholinergics) are given as first-line treatment and long-acting bronchodilators can be given in more symptomatic patients with greater functional impact.4
The Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program (NAEPP) recommend a stepwise approach to achieve sufficient control of asthma, including reduction in the risk of exacerbations. If control is not achieved, an increase in controller therapy dose or the introduction of additional maintenance therapies are recommended.5
Acebrophylline has been widely used as an inexpensive oral treatment of asthma, and COPD.6,7 Previously, this drug known to have long clinical effectiveness to bronchodilation, however it also showed to have anti-inflammatory actions.6,7 Acebrophylline have been developed with the expectation that such drugs would have greater potency than theophylline, but with an improved side effect profile.8
Thus acebrophylline may prove beneficial in respiratory conditions including asthma but there is scarce evidence to support this. Hence our study aims to analyse the role of Acebrophylline in asthma.
We invite you to participate in this data collection activity. All you need to do is to report on a standard form your experience with acebrophylline in the normal course of your practice. If you agree to participate, you will need to fill data collection forms (which we call DCF).
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})